Ken Keyong Ren - Net Worth and Insider Trading
Ken Keyong Ren Net Worth
The estimated net worth of Ken Keyong Ren is at least $8,400 dollars as of 2024-11-13. Ken Keyong Ren is the CEO and Director of CASI Pharmaceuticals Inc and owns about 1,500 shares of CASI Pharmaceuticals Inc (CASI) stock worth over $8,400. Details can be seen in Ken Keyong Ren's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Ken Keyong Ren has not made any transactions after 2016-01-19 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Ken Keyong Ren
Ken Keyong Ren Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Ken Keyong Ren owns 1 companies in total, including CASI Pharmaceuticals Inc (CASI) .
Click here to see the complete history of Ken Keyong Ren’s form 4 insider trades.
Insider Ownership Summary of Ken Keyong Ren
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
CASI | CASI Pharmaceuticals Inc | 2016-01-19 | Chief Executive Officer |
Ken Keyong Ren Latest Holdings Summary
Ken Keyong Ren currently owns a total of 1 stock. Ken Keyong Ren owns 1,500 shares of CASI Pharmaceuticals Inc (CASI) as of January 19, 2016, with a value of $8,400.
Latest Holdings of Ken Keyong Ren
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
CASI | CASI Pharmaceuticals Inc | 2016-01-19 | 1,500 | 5.60 | 8,400 |
Holding Weightings of Ken Keyong Ren
Ken Keyong Ren Form 4 Trading Tracker
According to the SEC Form 4 filings, Ken Keyong Ren has made a total of 0 transactions in CASI Pharmaceuticals Inc (CASI) over the past 5 years. The most-recent trade in CASI Pharmaceuticals Inc is the acquisition of 1,500 shares on January 19, 2016, which cost Ken Keyong Ren around $10,950.
Insider Trading History of Ken Keyong Ren
- 1
Ken Keyong Ren Trading Performance
GuruFocus tracks the stock performance after each of Ken Keyong Ren's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ken Keyong Ren is 73.24%. GuruFocus also compares Ken Keyong Ren's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ken Keyong Ren within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Ken Keyong Ren's insider trading performs compared to the benchmark.
Performance of Ken Keyong Ren
Ken Keyong Ren Ownership Network
Ownership Network List of Ken Keyong Ren
Ownership Network Relation of Ken Keyong Ren
Ken Keyong Ren Owned Company Details
What does CASI Pharmaceuticals Inc do?
Who are the key executives at CASI Pharmaceuticals Inc?
Ken Keyong Ren is the Chief Executive Officer of CASI Pharmaceuticals Inc. Other key executives at CASI Pharmaceuticals Inc include director & 10 percent owner & Chairman and CEO Wei-wu He , Chief Financial Officer Weihao Xu , and President Larry Zhang .
CASI Pharmaceuticals Inc (CASI) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of CASI Pharmaceuticals Inc (CASI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of CASI Pharmaceuticals Inc (CASI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
CASI Pharmaceuticals Inc (CASI)'s detailed insider trading history can be found in Insider Trading Tracker table.
CASI Pharmaceuticals Inc Insider Transactions
Ken Keyong Ren Mailing Address
Above is the net worth, insider trading, and ownership report for Ken Keyong Ren. You might contact Ken Keyong Ren via mailing address: 9640 Medical Center Drive, Rockville Md 20850.